High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system (Q81299205)

From Wikidata

Jump to navigation Jump to search

scientific article published on 16 May 2008

Language	Label	Description	Also known as
English	High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system	scientific article published on 16 May 2008

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18487992%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18487992%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

immunohistochemistry

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Allen M Gown

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18487992%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Lynn C Goldstein

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18487992%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Todd S Barry

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18487992%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Steven J Kussick

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18487992%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Patricia L Kandalaft

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18487992%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Patricia M Kim

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18487992%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Christopher C Tse

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18487992%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

publication date

16 May 2008

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18487992%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Modern Pathology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18487992%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18487992%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18487992%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1271-1277

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18487992%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

https://scigraph.springernature.com/pub.10.1038/modpathol.2008.83

0 references

HER-2 testing in breast cancer using parallel tissue-based methods.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

No rational theory for drug pricing

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Refinement of immunohistologic parameters for Her2/neu scoring validation by FISH and CISH.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Concordance between central and local laboratory HER2 testing from a community-based clinical study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased HER2 with U.S. Food and Drug Administration-approved antibody

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q81299205&oldid=2037823293"